# US 2009/0291992 A1 · Androgen receptor-ablative agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0291992 A1
- Document ID: US20090291992A1
- Status: Published application
- Kind: A1
- Application number: 12/389,759
- Filed: 2009-02-20
- Published: 2009-11-26
- Earliest claimed: 2008-02-22
- Assignees: The Ohio State University Research Foundation
- Inventors: Ching-Shih Chen; Dasheng Wang; Jian Yang
- Web page: https://patentgrep.com/patent/US20090291992A1

## CPC

- C07D 277/34: Oxygen atoms
- A61P 35/00: Antineoplastic agents
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of the thiazolidinedione family are provided and shown to be effective androgen receptor ablative agents that can be used in methods of treating or preventing cancer or precancer, including prostate cancer. Also provided are methods of treating or preventing cancer by administering a therapeutically effective amount of one of the androgen receptor ablative agents to a subject in need of such treatment.

## Claims

### Claim 1

A compound of Formula I:
wherein R1 is selected from the group consisting of hydroxyl, amino, halo, hydroxyalkyl, alkylmethoxy, cycloalkylmethoxy, arylmethoxy, NHCOR, NHSO2R, and CH2R;
wherein R2 is selected from the group consisting of hydrogen, halo, amino, methoxy, ethoxy, nitro, phenyl, di-alkyl, di-halo, trifluoromethyl, and hydroxyl;
wherein R3 is selected from the group consisting of hydrogen, alkyl, cyclic alkyl, and arylmethoxy;
and derivatives and metabolites thereof.

### Claim 2 (depends on 1)

A compound of claim 1, wherein the compound is selected from the group consisting of:
a. 5-[3-(1-Methyl-cyclohexylmethoxy)-benzylidene]-thiazolidine-2,4-dione
b. 5-(2-Hydroxy-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
c. 5-(3-Hydroxy-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione

### Claim 3 (depends on 1)

A compound of claim 1, wherein the compound is

### Claim 4

A compound of Formula II:
wherein R is selected from the group consisting of hydrogen, alkyl, allyl, nitrile, ester, carbonyl, amide, and aryl;
wherein R2 is selected from the group consisting of hydrogen, halo, amino, methoxy, ethoxy, nitro, phenyl, di-alkyl, di-halo, trifluoromethyl, and hydroxyl;
wherein R3 is selected from the group consisting of hydrogen, allyl, cyclic alkyl, and arylmethoxy;
and derivatives and metabolites thereof.

### Claim 5 (depends on 4)

The compound of claim 4, wherein the compound is selected from the group consisting of:
5-[3-Bromo-4-(6-methoxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 5-[3-Bromo-4-(6-ethoxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 5-[3-Bromo-4-(2,5,7,8-tetramethyl-6-propoxy-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 5-[3-Bromo-4-(6-butoxy-2,7,8-trimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 5-[3-Bromo-4-(2,5,7,8-tetramethyl-6-pentyloxy-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 5-[3-Bromo-4-(6-hexyloxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 5-[3-Bromo-4-(6-heptyloxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 5-[3-Bromo-4-(6-isopropoxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 5-[3-Bromo-4-(6-sec-butoxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 5-[3-Bromo-4-(6-isobutoxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 5-{3-Bromo-4-[2,5,7,8-tetramethyl-6-(3-methyl-butoxy)-chroman-2-ylmethoxy]-benzylidene}-thiazolidine-2,4-dione; 5-{3-Bromo-4-[2,5,7,8-tetramethyl-6-(4-methyl-pentyloxy)-chroman-2-ylmethoxy]-benzylidene}-thiazolidine-2,4-dione; 5-[3-Bromo-4-(6-but-2-enyloxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 5-[3-Bromo-4-(2,5,7,8-tetramethyl-6-pent-2-enyloxy-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 5-[4-(6-Allyloxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-3-trifluoromethyl-benzylidene]-thiazolidine-2,4-dione; 5-[4-(6-Butoxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-3-trifluoromethyl-benzylidene]-thiazolidine-2,4-dione; 5-[4-(2,5,7,8-Tetramethyl-6-pentyloxy-chroman-2-ylmethoxy)-3-trifluoromethyl-benzylidene]-thiazolidine-2,4-dione; 5-[4-(6-Hexyloxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-3-trifluoromethyl-benzylidene]-thiazolidine-2,4-dione; {2-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-acetonitrile; 3-{2-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-propionitrile; 4-{2-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-butyronitrile; 6-{2-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-hexanenitrile; 7-{6-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-1,3,4,6-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy}-heptanenitrile; 6-{2-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-2,2-dimethyl-hexanenitrile; 4-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-butyronitrile; 6-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-hexanenitrile; 6-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-2,2-dimethyl-hexanenitrile; 7-{6-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-1,3,4,6-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy}-heptanenitrile; 4-{6-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-1,3,4,6-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxymethyl}-benzonitrile; 5-[4-(6-Butoxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-3-methoxy-benzylidene]-thiazolidine-2,4-dione; 7-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-methoxy-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-heptanenitrile; 5-{2-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-pentanoic acid methyl ester; 5-{6-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-1,3,4,6-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy}-pentanoic acid ethyl ester; 5-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-pentanoic acid methyl ester; 5-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-pentanoic acid ethyl ester; 6-{2-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-hexanoic acid ethyl ester; 7-{2-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-heptanoic acid amide; 4-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-butyric acid ethyl ester; 5-[3-Bromo-4-(6-butoxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione; 4-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxymethyl}-benzonitrile; and 5-[4-(6-Butoxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-3-methoxy-benzylidene]-thiazolidine-2,4-dione.

### Claim 6 (depends on 5)

The compounds of claim 5, wherein the compound is selected from the group consisting of:
a. 5-[3-Bromo-4-(6-methoxy-2,5,1,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione
b. 5-[3-Bromo-4-(6-ethoxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione
c. 5-[3-Bromo-4-(2,5,7,8-tetramethyl-6-propoxy-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione
d. 5-[3-Bromo-4-(6-butoxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzylidene]-thiazolidine-2,4-dione
e. 4-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxymethyl}-benzonitrile
f. 5-[4-(6-Butoxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-3-methoxy-benzylidene]-thiazolidine-2,4-dione
g. 7-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-methoxy-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-heptanenitrile
h. 5-{2-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-pentanoic acid methyl ester
i. 5-{6-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-1,3,4,6-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy}-pentanoic acid ethyl ester
j. 5-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-pentanoic acid methyl ester
k. 5-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-pentanoic acid ethyl ester
l. 6-{2-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-hexanoic acid ethyl ester
m. 7-{2-[2-Bromo-4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-heptanoic acid amide
n. 4-{2-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yloxy}-butyric acid ethyl ester

### Claim 7

A compound of Formula III:
wherein R2 is selected from the group consisting of hydrogen, halo, amino, methoxy, ethoxy, nitro, phenyl, di-alkyl, di-halo, trifluoromethyl, and hydroxyl;
and derivatives and metabolites thereof.

### Claim 8 (depends on 7)

A compound of claim 7, wherein the compound is selected from the group consisting of:
a. 5-[3-Bromo-4-(1-methyl-cyclohexylmethoxy)-benzylidene]-thiazolidine-2,4-dione
b. 5-[4-(1-Methyl-cyclohexylmethoxy)-3-nitro-benzylidene]-thiazolidine-2,4-dione
c. 5-[4-(1-Methyl-cyclohexylmethoxy)-3-trifluoromethyl-benzylidene]-thiazolidine-2,4-dione
d. 5-[3-Methoxy-4-(1-methyl-cyclohexylmethoxy)-benzylidene]-thiazolidine-2,4-dione
e. 5-[3-Ethoxy-4-(1-methyl-cyclohexylmethoxy)-benzylidene]-thiazolidine-2,4-dione
f. 5-[3,5-Dimethyl-4-(1-methyl-cyclohexylmethoxy)-benzylidene]-thiazolidine-2,4-dione
and
g. 5-[4-(1-Methyl-cyclohexylmethoxy)-naphthalen-1-ylmethylene]-thiazolidine-2,4-dione

### Claim 9

A compound of Formula IV:
wherein R2 is selected from the group consisting of hydrogen, halo, amino, methoxy, ethoxy, nitro, phenyl, di-alkyl, di-halo, trifluoromethyl, and hydroxyl;
and derivatives and metabolites thereof.

### Claim 10 (depends on 9)

A compound of claim 9, wherein the compound is selected from the group consisting of:
a. 5-(4-Hydroxy-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
b. 5-(4-Hydroxy-3-trifluoromethyl-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
c. 5-(4-Hydroxy-3-nitro-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
d. 5-(3-Bromo-4-hydroxy-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
e. 5-(4-Hydroxy-3-methoxy-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
f. 5-(3,5-Dibromo-4-hydroxy-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
g. 5-(4-Hydroxy-3-iodo-5-methoxy-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
h. 5-(4-Hydroxy-3,5-dimethyl-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
and
i. 5-(4-Hydroxy-naphthalen-1-ylmethylene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione

### Claim 11

A compound of Formula V:
wherein R3 is selected from the group consisting of hydrogen, alkyl, cyclic alkyl, and arylmethoxy;
and derivatives and metabolites thereof.

### Claim 12 (depends on 10)

The compounds of claim 10, wherein the compounds are selected from the group consisting of:
a. 5-(3-Bromo-4-hydroxy-benzylidene)-3-ethyl-thiazolidine-2,4-dione
b. 5-(3-Bromo-4-hydroxy-benzylidene)-3-propyl-thiazolidine-2,4-dione
c. 5-(3-Bromo-4-hydroxy-benzylidene)-3-butyl-thiazolidine-2,4-dione
d. 5-(3-Bromo-4-hydroxy-benzylidene)-3-pentyl-thiazolidine-2,4-dione
e. 5-(3-Bromo-4-hydroxy-benzylidene)-3-isopropyl-thiazolidine-2,4-dione
f. 5-(3-Bromo-4-hydroxy-benzylidene)-3-(4-methyl-pentyl)-thiazolidine-2,4-dione
g. 5-(3-Bromo-4-hydroxy-benzylidene)-3-cyclohexylmethyl-thiazolidine-2,4-dione
h. 3-Allyl-5-(3-bromo-4-hydroxy-benzylidene)-thiazolidine-2,4-dione
i. 5-(3-Bromo-4-hydroxy-benzylidene)-3-(3-methyl-but-2-enyl)-thiazolidine-2,4-dione
j. 3-Benzyl-5-(3-bromo-4-hydroxy-benzylidene)-thiazolidine-2,4-dione
k. 4-[5-(3-Bromo-4-hydroxy-benzylidene)-2,4-dioxo-thiazolidin-3-ylmethyl]-benzonitrile
l. 4-[5-(3-Bromo-4-hydroxy-benzylidene)-2,4-dioxo-thiazolidin-3-yl]-butyronitrile
m. 4-[5-(3-Bromo-4-hydroxy-benzylidene)-2,4-dioxo-thiazolidin-3-yl]-butyric acid ethyl ester
n. 6-[5-(3-Bromo-4-hydroxy-benzylidene)-2,4-dioxo-thiazolidin-3-yl]-2,2-dimethyl-hexanenitrile
o. 5-(3-Bromo-4-hydroxy-benzylidene)-3-(tetrahydro-pyran-2-ylmethyl)-thiazolidine-2,4-dione
p. 5-(3-Bromo-4-hydroxy-benzylidene)-3-(6,6-dimethyl-[1,3]dioxan-4-ylmethyl)-thiazolidine-2,4-dione
q. 5-(3-Bromo-4-hydroxy-benzylidene)-3-naphthalen-1-ylmethyl-thiazolidine-2,4-dione
r. 5-(3-Bromo-4-hydroxy-benzylidene)-3-(3-chloro-5-fluoro-benzyl)-thiazolidine-2,4-dione
s. 5-(3-Bromo-4-hydroxy-benzylidene)-3-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-thiazolidine-2,4-dione
t. 3-(4-Benzoyl-benzyl)-5-(3-bromo-4-hydroxy-benzylidene)-thiazolidine-2,4-dione
u. 4′-[5-(3-Bromo-4-hydroxy-benzylidene)-2,4-dioxo-thiazolidin-3-ylmethyl]-biphenyl-2-carbonitrile

### Claim 13

A compound of Formula VI:
wherein R3 is selected from the group consisting of hydrogen, alkyl, cyclic allyl, and arylmethoxy;
and derivatives and metabolites thereof.

### Claim 14 (depends on 13)

The compounds of claim 13, wherein the compounds are selected from the group consisting of:
a. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-ethyl-thiazolidine-2,4-dione
b. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-propyl-thiazolidine-2,4-dione
c. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-butyl-thiazolidine-2,4-dione
d. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-pentyl-thiazolidine-2,4-dione
e. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-isopropyl-thiazolidine-2,4-dione
f. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-(4-methyl-pentyl)-thiazolidine-2,4-dione
g. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-cyclohexylmethyl-thiazolidine-2,4-dione
h. 3-Allyl-5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-thiazolidine-2,4-dione
i. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-(3-methyl-but-2-enyl)-thiazolidine-2,4-dione
j. 3-Benzyl-5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-thiazolidine-2,4-dione
k. 4-[5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-2,4-dioxo-thiazolidin-3-ylmethyl]-benzonitrile
l. 4-[5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-2,4-dioxo-thiazolidin-3-yl]-butyronitrile
m. 4-[5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-2,4-dioxo-thiazolidin-3-yl]-butyric acid ethyl ester
n. 6-[5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-2,4-dioxo-thiazolidin-3-yl]-2,2-dimethyl-hexanenitrile
o. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-(tetrahydro-pyran-2-ylmethyl)-thiazolidine-2,4-dione
p. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-(6,6-dimethyl-[1,3]dioxan-4-ylmethyl)-thiazolidine-2,4-dione
q. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-naphthalen-1-ylmethyl-thiazolidine-2,4-dione
r. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-(3-chloro-5-fluoro-benzyl)-thiazolidine-2,4-dione
s. 5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-3-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-thiazolidine-2,4-dione
t. 3-(4-Benzoyl-benzyl)-5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-thiazolidine-2,4-dione
u. 4′-[5-(3-Trifluoromethyl-4-hydroxy-benzylidene)-2,4-dioxo-thiazolidin-3-ylmethyl]-biphenyl-2-carbonitrile

### Claim 15

A compound of Formula VII:
wherein R1 is selected from the group consisting of hydroxyl, amino, halo, hydroxyalkyl, alkylmethoxy, cycloalkylmethoxy, arylmethoxy, NHCOR, NHSO2R, and CH2R;
wherein R2 is selected from the group consisting of hydrogen, bromo, and trifluoromethyl;
and derivatives and metabolites thereof.

### Claim 16 (depends on 15)

The compounds of claim 15, wherein the compounds are selected from the group consisting of:
a. 5-(4-Fluoro-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
b. 5-(4-Chloro-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
c. 5-(4-Bromo-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
d. 3-(1-Methyl-cyclohexylmethyl)-5-(4-nitro-benzylidene)-thiazolidine-2,4-dione
e. 3-(1-Methyl-cyclohexylmethyl)-5-(4-trifluoromethoxy-benzylidene)-thiazolidine-2,4-dione
f. 5-(4-Diethylamino-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
g. 5-(4-Dimethylamino-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
h. 5-(4-Hydroxymethyl-benzylidene)-3-(1-methyl-cyclohexylmethyl)-thiazolidine-2,4-dione
i. 4-[3-(1-Methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-benzonitrile
j. 4-[3-(1-Methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-benzaldehyde
k. 4-[3-(1-Methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-benzoic acid methyl ester
l. 4-[3-(1-Methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-benzoic acid
m. N-{4-[3-(1-Methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-acetamide
n. N-{4-[3-(1-Methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-propionamide
o. Hexadecanoic acid {4-[3-(1-methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-amide
p. Cyclohexanecarboxylic acid {4-[3-(1-methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-amide
q. 2,2,2-Trichloro-N-{4-[3-(1-methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-acetamide
r. N-{4-[3-(1-Methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-benzamide
s. N-{4-[3-(1-Methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-methanesulfonamide
t. N-{4-[3-(1-Methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-2-nitro-benzenesulfonamide
u. N-(4-{4-[3-(1-Methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenylsulfamoyl}-phenyl)-acetamide
v. 4-Methyl-N-{4-[3-(1-methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-benzenesulfonamide
w. 4-Chloro-N-{4-[3-(1-methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-benzenesulfonamide
x. 4-(Z)-Acetyl-N-{4-[3-(1-methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-benzenesulfonamide
y. N-{4-[3-(1-Methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-4-nitro-benzenesulfonamide
z. N-{4-[3-(1-Methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-4-nitro-3-trifluoromethyl-benzenesulfonamide
aa. 4-Chloro-N-{4-[3-(1-methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-3-nitro-benzenesulfonamide
ab. 2-Methoxy-N-{4-[3-(1-methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-4-nitro-benzenesulfonamide
ac. 3,4-Dimethoxy-N-{4-[3-(1-methyl-cyclohexylmethyl)-2,4-dioxo-thiazolidin-5-ylidenemethyl]-phenyl}-benzenesulfonamide

### Claim 17

A method of treating, inhibiting, or delaying the onset of a cancer in a subject in need of treatment, the method comprising administering a therapeutically effective amount of a compound of Formula I:
wherein R1 is selected from the group consisting of hydroxyl, amino, halo, hydroxyalkyl, alkylmethoxy, cycloalkylmethoxy, arylmethoxy, NHCOR, NHSO2R, and CH2R;
wherein R2 is selected from the group consisting of hydrogen, halo, amino, methoxy, ethoxy, nitro, phenyl, di-alkyl, di-halo, trifluoromethyl, and hydroxyl;
wherein R3 is selected from the group consisting of hydrogen, allyl, cyclic allyl, and arylmethoxy;
or a pharmaceutically-acceptable salt thereof, to the subject in need of such treatment.

### Claim 18 (depends on 17)

The method of claim 17, wherein the cancer is selected from the group consisting of leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, bladder cancer, lymphoma, and breast cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cancer is prostate cancer.

### Claim 20 (depends on 19)

The method of claim 19, wherein the prostate cancer is hormone-refractory prostate cancer (HRPC).
